Gut,
Journal Year:
2008,
Volume and Issue:
57(8), P. 1140 - 1155
Published: April 8, 2008
A
multitude
of
physiological
effects
and
putative
pathophysiological
roles
have
been
proposed
for
the
endogenous
cannabinoid
system
in
gastrointestinal
tract,
liver
pancreas.
These
range
from
on
epithelial
growth
regeneration,
immune
function,
motor
appetite
control,
fibrogenesis
secretion.
Cannabinoids
potential
therapeutic
application
gut
diseases.
Two
exciting
applications
area
reversing
hepatic
fibrosis
as
well
antineoplastic
may
a
significant
impact
these
This
review
critically
appraises
experimental
clinical
evidence
supporting
receptor-based
drugs
gastrointestinal,
pancreatic
Application
modern
pharmacological
principles
will
most
probably
expand
selective
modulation
peripherally
humans.
We
anticipate
that,
addition
to
approval
several
countries
CB1
antagonist,
rimonabant,
treatment
obesity
associated
metabolic
dysfunctions,
other
modulators
are
likely
an
human
disease
future,
including
neoplasia.
Physiological Reviews,
Journal Year:
2009,
Volume and Issue:
89(1), P. 309 - 380
Published: Jan. 1, 2009
The
discovery
of
cannabinoid
receptors
and
subsequent
identification
their
endogenous
ligands
(endocannabinoids)
in
early
1990s
have
greatly
accelerated
research
on
actions
the
brain.
Then,
2001
that
endocannabinoids
mediate
retrograde
synaptic
signaling
has
opened
up
a
new
era
for
also
established
concept
how
diffusible
messengers
modulate
efficacy
neural
activity.
last
7
years
witnessed
remarkable
advances
our
understanding
endocannabinoid
system.
It
is
now
well
accepted
are
released
from
postsynaptic
neurons,
activate
presynaptic
CB(1)
receptors,
cause
transient
long-lasting
reduction
neurotransmitter
release.
In
this
review,
we
aim
to
integrate
current
functions
system,
especially
focusing
control
transmission
We
summarize
recent
electrophysiological
studies
carried
out
synapses
various
brain
regions
discuss
regulated
by
signaling.
Then
refer
anatomical
subcellular
distribution
molecules
involved
these
arranged
around
synapses.
addition,
make
brief
overview
intracellular
signaling,
biochemical
metabolism,
behavioral
roles
system
aspects
functions.
Proceedings of the National Academy of Sciences,
Journal Year:
2009,
Volume and Issue:
106(38), P. 16511 - 16516
Published: Sept. 4, 2009
GPR55
is
a
G
protein-coupled
receptor
recently
shown
to
be
activated
by
certain
cannabinoids
and
lysophosphatidylinositol
(LPI).
However,
the
physiological
role
of
remains
unknown.
Given
recent
finding
that
cannabinoid
receptors
CB(1)
CB(2)
affect
bone
metabolism,
we
examined
in
biology.
was
expressed
human
mouse
osteoclasts
osteoblasts;
expression
higher
than
macrophage
progenitors.
Although
agonists
O-1602
LPI
inhibited
osteoclast
formation
vitro,
these
ligands
stimulated
polarization
resorption
vitro
caused
activation
Rho
ERK1/2.
These
stimulatory
effects
on
function
were
attenuated
generated
from
GPR55(-/-)
macrophages
antagonist
cannabidiol
(CBD).
Furthermore,
treatment
mice
with
this
non-psychoactive
constituent
cannabis
significantly
reduced
vivo.
Consistent
ability
suppress
but
stimulate
function,
histomorphometric
microcomputed
tomographic
analysis
long
bones
male
revealed
increased
numbers
morphologically
inactive
significant
increase
volume
thickness
trabecular
presence
unresorbed
cartilage.
data
reveal
physiology
regulating
number
function.
In
addition,
study
also
brings
light
an
effect
both
endogenous
ligand,
LPI,
constituent,
CBD,
turnover
The FASEB Journal,
Journal Year:
2008,
Volume and Issue:
23(1), P. 183 - 193
Published: Aug. 29, 2008
The
endogenous
phospholipid
l-alpha-lysophosphatidylinositol
(LPI)
was
recently
identified
as
a
novel
ligand
for
the
orphan
G
protein-coupled
receptor
55
(GPR55).
In
this
study
we
define
downstream
signaling
pathways
activated
by
LPI
in
human
embryonic
kidney
(HEK)
293
cell
line
engineered
to
stably
express
recombinant
GPR55.
We
find
that
treatment
with
induces
marked
GPR55
internalization
and
stimulates
sustained,
oscillatory
Ca(2+)
release
pathway,
which
is
dependent
on
Galpha13
requires
RhoA
activation.
then
establish
cascade
leads
efficient
activation
of
NFAT
(nuclear
factor
T
cells)
family
transcription
factors
their
nuclear
translocation.
Analysis
cannabinoid
activity
at
revealed
no
clear
effect
endocannabinoids
anandamide
2-arachidonoylglycerol;
however,
classical
CB(1)
antagonist
AM251
evoked
GPR55-mediated
signaling.
Thus,
potent
efficacious
GPR55,
likely
be
key
plasma
membrane
mediator
LPI-mediated
events
changes
gene
expression.
European Journal of Pain,
Journal Year:
2015,
Volume and Issue:
20(6), P. 936 - 948
Published: Oct. 30, 2015
Current
arthritis
treatments
often
have
side-effects
attributable
to
active
compounds
as
well
route
of
administration.
Cannabidiol
(CBD)
attenuates
inflammation
and
pain
without
side-effects,
but
CBD
is
hydrophobic
has
poor
oral
bioavailability.
Topical
drug
application
avoids
gastrointestinal
administration,
first
pass
metabolism,
providing
more
constant
plasma
levels.This
study
examined
efficacy
transdermal
for
reduction
in
pain,
assessing
any
adverse
effects
a
rat
complete
Freund's
adjuvant-induced
monoarthritic
knee
joint
model.
gels
(0.6,
3.1,
6.2
or
62.3
mg/day)
were
applied
4
consecutive
days
after
induction.
Joint
circumference
immune
cell
invasion
histological
sections
measured
indicate
level
inflammation.
Paw
withdrawal
latency
(PWL)
response
noxious
heat
stimulation
determined
nociceptive
sensitization,
exploratory
behaviour
ascertained
animal's
activity
level.Measurement
concentration
provided
by
absorption
revealed
linearity
with
0.6-6.2
mg/day
doses.
Transdermal
gel
significantly
reduced
swelling,
limb
posture
scores
rating
spontaneous
infiltration
thickening
the
synovial
membrane
dose-dependent
manner.
PWL
recovered
near
baseline
level.
Immunohistochemical
analysis
spinal
cord
(CGRP,
OX42)
dorsal
root
ganglia
(TNFα)
reductions
pro-inflammatory
biomarkers.
Results
showed
62
effective
Exploratory
was
not
altered
indicating
limited
effect
on
higher
brain
function.These
data
that
topical
therapeutic
potential
relief
pain-related
behaviours
evident
side-effects.
Journal of Clinical Medicine,
Journal Year:
2019,
Volume and Issue:
8(7), P. 989 - 989
Published: July 8, 2019
Cannabidiol
(CBD)
is
ubiquitous
in
state-based
medical
cannabis
programs
and
consumer
products
for
complementary
health
or
recreational
use.
CBD
has
intrinsic
pharmacologic
effects
associated
adverse
drug
events
(ADEs)
along
with
the
potential
pharmacokinetic
pharmacodynamic
drug–drug
interactions
(DDIs).
Given
use
among
patients
complex
conditions
treatment
regimens,
as
well
its
expanded
use,
awareness
of
safety
issues
needed.
Prescribing
information
federally
approved
containing
were
reviewed.
Data
on
ADEs
DDIs
extracted
summarized.
Nearly
one-half
users
experienced
ADEs,
which
displayed
a
general
dose-response
relationship.
Common
include
transaminase
elevations,
sedation,
sleep
disturbances,
infection,
anemia.
common
biological
targets
implicated
metabolism
(e.g.,
CYP3A4/2C19)
excretion
P-glycoprotein),
commonly
used
medication
high.
General
clinical
recommendations
reducing
substrate
doses,
monitoring
finding
alternative
therapy
should
be
considered,
especially
medically
patients.
both
victim
perpetrator
own
ADE
profile.
These
considered
risk-benefit
assessment
consumers
made
aware